Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. Kummar S, et al. Among authors: chen ap. Invest New Drugs. 2016 Jun;34(3):355-63. doi: 10.1007/s10637-016-0335-x. Epub 2016 Mar 21. Invest New Drugs. 2016. PMID: 26996385 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A, et al. Grem JL, et al. J Clin Oncol. 1994 Mar;12(3):560-8. doi: 10.1200/JCO.1994.12.3.560. J Clin Oncol. 1994. PMID: 8120554 Clinical Trial.
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Shapiro JD, Harold N, Takimoto C, Hamilton JM, Vaughn D, Chen A, Steinberg SM, Liewehr D, Allegra C, Monahan B, Lash A, Grollman F, Flemming D, Behan K, Johnston PG, Haller D, Quinn M, Morrison G, Grem JL. Shapiro JD, et al. Clin Cancer Res. 1999 Sep;5(9):2399-408. Clin Cancer Res. 1999. PMID: 10499610 Clinical Trial.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ. Kummar S, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7. doi: 10.1158/1078-0432.CCR-07-0791. Clin Cancer Res. 2007. PMID: 17875771 Clinical Trial.
334 results